PEG MGF refers to pegylated mechano growth factor. This is a spliced variant of the IGF gene that is used by animals to increase their stem cell count within the muscle tissue while encouraging muscle fibers to mature and fuse.

This system is largely used to produce adult muscle as rats mature. The natural version of this peptide is developed where needed and does not travel through the bloodstream; synthetic versions of this chemical have been altered so they may remain stable in the bloodstream for a few minutes.

Pegylation refers to the chemical’s ability to attract polyethylene glycol from larger molecules. In this case, the peptide is specifically designed to fuel the breakdown of MGF. PEG molecules can act as a protective coating for the portion of MGF they attract. In theory this would allow MGF to be carried through the bloodstream without being broken down so it can reach its destination more successfully.

Therapeutic Potential for Skeletal Muscle Repair

Aging, cancer, motor neuron degeneration, ischemia, heart failure and other conditions which lack effective treatments will have an effect on the skeletal muscle, but IGF-1 can be used to stimulate repair of these tissues.


Preclinical studies of animal test subjects have indicated that IGF-1 can be used to increase the strength and mass of muscles, to reduce degeneration and inhibit the excessive inflammatory process that is caused by toxic injury.

Applying IGF-1 has also been seen to cause proliferation of the satellite cells where it was applied.

These trials have not found an effective delivery method for the peptides. It will be necessary to choose isoforms or peptides, such as PEG MGF, that are capable of providing targeted deliveries while still standing up in the bloodstream.

Mechano Growth Factor Uses

Biologically active peptides that are derived from E peptide forms can be used to create a splice variant of IGF, known as MGF. which offers an increased stability once applied to the animal’s body.

Inventors found that the native versions of MGF C terminal have a very short half-life when applied to plasma, which requires stabilizing modifications if these chemicals are to be used in pharmacological settings.

It has been demonstrated that MGF C terminal peptides contain cardioprotective and neruoprotective agents. They also contain the potential to increase the strength of dystrophic and normal skeletal muscle tissues.

This invention includes a polypeptide that is made up of 50 amino acid residues that compromise the sequence of the amino acids when they are applied to the C terminal, similar to the function of IGF-1.

Intranasal Delivery to the Brain

Neurodegenration is caused by the loss of function or structure of the neurons and therapeutic methods are being created, to better address the symptoms of this condition.

Currently delivery strategies such as intracarotid infusions, catheters, surgery or chemotherapy are used to treat these conditions, but these methods are quite invasive and pose risks to the animal.

Studies are noting that using peptides such as MGF or TAT to deliver pegylated chitosan nanoparticles for siRNA delivery can help to bypass the blood brain barrier without risk.

Current studies suggest that .5 mg/kg is the appropriate administration level to repair damage to the hypothalamus, hippocampus and thalamus.

MGF is produced when muscle fiber is broken down via weight training as well. This stimulates muscle growth in animals and allows the body of the animal to produce new muscle fiber. It can also increase protein synthesis and promotes the retention of nitrogen in test subjects, like mice.

These effects are commonly seen promoting growth throughout a maturing animal’s body or as a means of improving the physique of the animal. The results are often dependent on administration of the peptide.